This is a working overview of TB-500, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-08. Anything still debated is marked as such rather than presented as settled.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
== Recognition == In August 2024, Dei BioPharma was awarded "Best Pharma Company" at the African Excellence Awards hosted by MEA Markets in London. Members of the Ugandan Parliament commended the company for pioneering drug development in underrepresented areas such as oncology and vaccine production.
== Pathways == The protein C pathways are the specific chemical reactions that control the level of expression of APC and its activity in the body. Protein C is pleiotropic, with two main classes of functions: anticoagulation and cytoprotection (its direct effect on cells). Which function protein C performs depends on whether or not APC remains bound to EPCR after it is activated; the anticoagulative effects of APC occur when it does not. In this case, protein C functions as an anticoagulant by irreversibly proteolytically inactivating Factor Va and Factor VIIIa, turning them into Factor Vi and Factor VIIIi respectively. When still bound to EPCR, activated protein C performs its cytoprotective effects, acting on the effector substrate PAR-1, protease-activated receptor-1. To a degree, APC's anticoagulant properties are independent of its cytoprotective ones, in that expression of one pathway is not affected by the existence of the other. The activity of protein C may be down-regulated by reducing the amount either of available thrombomodulin or of EPCR. This may be done by inflammatory cytokines, such as interleukin-1β (IL-1β ) and tumor necrosis factor-α (TNF-α). Activated leukocytes release these inflammatory mediators during inflammation, inhibiting the creation of both thrombomodulin and EPCR, and inducing their shedding from the endothelial surface. Both of these actions down-regulate protein C activation. Thrombin itself may also have an effect on the levels of EPCR.
=== Definition by Waterlow === In the 1970s, John Conrad Waterlow established a new classification system for malnutrition. Instead of using just weight for age measurements, Waterlow's system combines weight-for-height (indicating acute episodes of malnutrition) with height-for-age to show the stunting that results from chronic malnutrition. One advantage of the Waterlow classification is that weight for height can be calculated even if a child's age is unknown.
Forced to retreat, Alexios ceded the city of Dyrrachium to the Count of the Tent (or Byzantine provincial administrators) mobilizing from Arbanon (i.e., ἐξ Ἀρβάνων ὁρμωμένω Κομισκόρτη; the term Κομισκόρτη is short for κόμης της κόρτης meaning "Count of the Tent"). The city's garrison resisted until February 1082, when Dyrrachium was betrayed to the Normans by the Venetian and Amalfitan merchants who had settled there. The Normans were now free to penetrate into the hinterland; they took Ioannina and some minor cities in southwestern Macedonia and Thessaly before appearing at the gates of Thessalonica. Dissension among the high ranks coerced the Normans to retreat to Italy. They lost Dyrrachium, Valona, and Butrint in 1085, after the death of Robert. A few years after the First Crusade, in 1107, the Normans under the command of Bohemond, Robert's son, landed in Valona and besieged Dyrrachium using the most sophisticated military equipment of the time, but to no avail. Meanwhile, they occupied Petrela, the citadel of Mili at the banks of the river Deabolis, Gllavenica (Ballsh), Kanina and Jericho. This time, the Albanians sided with the Normans, dissatisfied by the heavy taxes the Byzantines had imposed upon them. With their help, the Normans secured the Arbanon passes and opened their way to Dibra. The lack of supplies, disease and Byzantine resistance forced Bohemond to retreat from his campaign and sign a peace treaty with the Byzantines in the city of Deabolis.
Sources: en.wikipedia.org
=== α2-Adrenergic receptor agonists === α2-Adrenergic receptor agonists like clonidine can improve sleep and may be useful in the treatment of insomnia. An example of this is in the treatment of insomnia in children and adolescents with attention deficit hyperactivity disorder (ADHD), for instance due stimulant therapy. Similarly to clonidine, the α2-adrenergic receptor agonist dexmedetomidine has sedative and hypnotic effects and is used to produce sedation in hospital settings. The sleep induced by dexmedetomidine is said to closely resemble natural sleep. The selective α2A-adrenergic receptor agonist tasipimidine (ODM-105) is under development for the treatment of insomnia and is in phase 2 clinical trials for this indication as of October 2024. α2-Adrenergic receptor agonists can produce hypotension and bradycardia as side effects, which has limited their use. Activation of the α2A-adrenergic receptor is thought to be responsible for most of the physiological effects of the α2-adrenergic receptors, including hypotension. On the other hand, the preferential α2A-adrenergic receptor agonist guanfacine appears to show less sedation and hypotension than clonidine. Tizanidine has been used off-label for sleep similarly to clonidine, but likewise shows less hypotensive potency in comparison.
== Mechanism == Most of the energy of the primary ions is dissipated into the near-surface region of the solid by a series of binary collisions. This results in ejection (sputtering) of so-called "secondary" particles such as electrons, atoms, molecules, and ions from the surface. In SIMS, it is these secondary ions which are detected and analyzed by a mass spectrometer to produce a mass spectrum of a surface for a detailed chemical analysis of the surface or the solid. The secondary-ion current is given by
=== Other sequences === Chain bridge, type of suspension bridge Chain crew, crew that manages signal poles in gridiron football Chain gang, group of prisoners chained together as a form of punishment Chain letter, a message that attempts to induce the recipient to make a number of copies of the message and then pass them on to one or more new recipients Chain of events, a number of actions and their effects that are linked together Chain smoking, practice of smoking several cigarettes/cigars in succession Chain stitch, in sewing and embroidery, a series of looped stitches that form a chain Chaining, a technique from applied behavioral analysis for teaching complicated tasks by breaking them into simpler steps Hudson River Chains, one of several chains used in blockades of the Hudson River Human chain (politics), a form of protest Signifying chain, in semiotics, an interlocking system of signifiers
=== Marinating swordfish === A traditional method marinating swordfish is to soak the swordfish into sake kasu. Normally, marinating food ingredients in sake kasu can increase the amount of inosine-monophosphate thus increasing the umami flavor of the dish. Soaking swordfish in sake kasu will decrease the amount of inosine-monophosphate in the swordfish and increase the level of inosine and the amount of inosine-monophosphate in the sake kasu marinade.
The famous "Tajiri-go" bull was born from the "Atsuta tsuru," which is a descendant of the Shusuke tsuru. According to a survey conducted by the Japan Wagyu Registry Association, the pedigree was traced from a database of 718,969 Japanese black cattle mothers registered in Japan, and it was found that 718,330 or 99.9% of them are descended from the Tajiri-go. On the other hand, there are those who are concerned about the current situation in which only the Tajima cattle line represented by the Tajiri-go is spreading and genetic diversity is being lost from Wagyu, and the movement to revive the Takenotani tsuru has been attracting attention in recent years. In 1859, Japan opened the port of Yokohama in accordance with the demands of Western nations. At the same time, a foreign settlement was established in Yokohama. Foreign residents sought cattle for meat from neighboring villages but were refused, so cattle were imported from the U.S., China, and Korea, which gradually became unable to meet the demand. In 1865, before the Port of Kobe was opened, the Hyogo Port Opening Demand Incident occurred, in which nine warships from Britain, France, the Netherlands, and the United States invaded Hyogo Port demanding its opening. At that time, sailors negotiated with local cattle merchants for cattle, which were initially slaughtered on board, but as demand increased, it became necessary to slaughter them on land. 1866 saw the first slaughter of cattle by foreigners in the pine forests of Cape Wadamisaki.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
Dry lyophilized powder is usually kept frozen, desiccated, and out of direct light. Sealed vials are not opened until needed, because moisture uptake can degrade short peptides. Longer archival storage is often done at lower temperatures than routine working stock.